Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Buys $1,015,803.36 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) major shareholder Venrock Healthcare Capital Par acquired 88,794 shares of the company’s stock in a transaction on Friday, February 14th. The shares were bought at an average price of $11.44 per share, with a total value of $1,015,803.36. Following the completion of the purchase, the insider now directly owns 4,148,428 shares of the company’s stock, valued at approximately $47,458,016.32. This represents a 2.19 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Wednesday, February 12th, Venrock Healthcare Capital Par acquired 8,971 shares of Oruka Therapeutics stock. The shares were bought at an average price of $11.86 per share, with a total value of $106,396.06.
• On Monday, February 10th, Venrock Healthcare Capital Par bought 574 shares of Oruka Therapeutics stock. The shares were acquired at an average price of $10.90 per share, for a total transaction of $6,256.60.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $10.15 on Friday. The firm has a 50-day moving average price of $14.29. The company has a market capitalization of $355.24 million, a PE ratio of -1.62 and a beta of 0.77. Oruka Therapeutics, Inc. has a 12-month low of $9.53 and a 12-month high of $53.88.

Hedge Funds Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ORKA. FMR LLC bought a new position in Oruka Therapeutics during the third quarter worth about $114,763,000. RTW Investments LP bought a new position in Oruka Therapeutics during the third quarter worth about $45,359,000. Vanguard Group Inc. boosted its holdings in Oruka Therapeutics by 4,161.2% during the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company’s stock worth $31,231,000 after buying an additional 1,572,853 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Oruka Therapeutics by 374.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,326,893 shares of the company’s stock worth $25,730,000 after buying an additional 1,047,245 shares during the last quarter. Finally, Franklin Resources Inc. bought a new position in Oruka Therapeutics during the third quarter worth about $17,661,000. Institutional investors own 56.44% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. Wedbush restated an “outperform” rating and set a $40.00 target price on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Finally, Wolfe Research assumed coverage on Oruka Therapeutics in a report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $39.86.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.